Phreesia, Inc.

DB:19P Stock Report

Market Cap: €1.5b

Phreesia Valuation

Is 19P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 19P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 19P (€24.4) is trading below our estimate of fair value (€68.63)

Significantly Below Fair Value: 19P is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 19P?

Key metric: As 19P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 19P. This is calculated by dividing 19P's market cap by their current revenue.
What is 19P's PS Ratio?
PS Ratio3.8x
SalesUS$405.14m
Market CapUS$1.52b

Price to Sales Ratio vs Peers

How does 19P's PS Ratio compare to its peers?

The above table shows the PS ratio for 19P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
NXU Nexus
4.4x9.5%€1.2b
COP CompuGroup Medical SE KGaA
1x1.9%€1.1b
M3V MeVis Medical Solutions
2.6xn/a€46.2m
AJ91 DocCheck
0.8xn/a€43.6m
19P Phreesia
3.8x11.0%€1.5b

Price-To-Sales vs Peers: 19P is expensive based on its Price-To-Sales Ratio (3.8x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 19P's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
19P 3.8xIndustry Avg. 2.3xNo. of Companies10PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 19P is expensive based on its Price-To-Sales Ratio (3.8x) compared to the European Healthcare Services industry average (2.3x).

Price to Sales Ratio vs Fair Ratio

What is 19P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

19P PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: 19P is expensive based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 19P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€24.40
€28.96
+18.7%
9.6%€34.50€23.00n/a14
Dec ’25€19.20
€27.74
+44.5%
10.1%€32.13€21.74n/a14
Nov ’25€16.70
€26.83
+60.7%
9.8%€31.10€21.04n/a15
Oct ’25€20.40
€26.55
+30.2%
9.5%€30.80€20.84n/a16
Sep ’25€22.80
€26.68
+17.0%
8.6%€31.34€21.20n/a16
Aug ’25€23.00
€26.68
+16.0%
8.6%€31.34€21.20n/a16
Jul ’25€19.50
€26.69
+36.9%
8.0%€31.22€21.12n/a16
Jun ’25€19.50
€27.42
+40.6%
9.2%€32.26€21.20n/a16
May ’25€19.30
€27.81
+44.1%
9.9%€34.16€21.24n/a16
Apr ’25€22.40
€27.81
+24.2%
9.9%€34.16€21.24n/a16
Mar ’25€22.80
€26.15
+14.7%
16.0%€33.18€15.67n/a16
Feb ’25€23.60
€25.34
+7.4%
15.3%€33.13€15.64n/a15
Jan ’25€21.20
€24.99
+17.9%
15.5%€32.98€15.57€24.4014
Dec ’24€14.00
€33.78
+141.3%
12.2%€40.27€27.16€19.2014
Nov ’24€12.90
€33.78
+161.8%
12.2%€40.27€27.16€16.7014
Oct ’24€17.50
€33.78
+93.0%
12.2%€40.27€27.16€20.4014
Sep ’24€26.20
€35.72
+36.3%
9.2%€42.13€27.47€22.8015
Aug ’24€28.80
€35.72
+24.0%
9.2%€42.13€27.47€23.0015
Jul ’24€27.40
€35.72
+30.4%
9.2%€42.13€27.47€19.5015
Jun ’24€28.00
€36.25
+29.5%
9.2%€42.75€27.88€19.5015
May ’24€28.40
€36.11
+27.1%
9.9%€42.15€27.49€19.3015
Apr ’24€28.13
€36.50
+29.8%
10.1%€42.44€27.68€22.4014
Mar ’24€34.57
€35.86
+3.7%
15.5%€43.54€24.08€22.8014
Feb ’24€34.18
€34.56
+1.1%
14.0%€42.32€23.92€23.6014
Jan ’24€30.85
€33.43
+8.4%
11.9%€38.38€24.34€21.2014

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:53
End of Day Share Price 2025/01/03 00:00
Earnings2024/10/31
Annual Earnings2024/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Phreesia, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph VruwinkBaird
Zhilin LongBerenberg
Richard CloseCanaccord Genuity